High LDL cholesterol is associated with dementia risk, but current evidence does not show that it directly causes Alzheimer's disease. LDL, or low-density lipoprotein, carries cholesterol in the blood and is often called "bad" cholesterol. The distinction matters because dementia describes impaired memory and thinking from many possible causes. Alzheimer's is a specific brain disease, and studies that combine dementia types cannot prove an Alzheimer's-specific effect.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the reported association mean?
- Why is causation still uncertain?
- Dementia diagnoses can hide mixed causes
- Do statins prevent Alzheimer's or dementia?
- What should someone with high LDL do?
What does the reported association mean?
The 2024 Lancet Commission identified high LDL in midlife as a modifiable risk factor for dementia. It estimated a relative risk of 1.3, meaning about 30% higher relative risk among people with high LDL compared with those without it. The Commission also calculated a population-attributable fraction of 7%.
This model estimates the proportion of dementia cases associated with midlife high LDL across a population. It does not mean that high LDL causes 7% of cases or that lowering LDL will prevent Alzheimer's. These figures describe an association, not a proven chain of cause and effect. The estimates also apply to dementia broadly, rather than biologically confirmed Alzheimer's disease, as detailed in the 2024 Lancet Commission report.
Why is causation still uncertain?
Several factors could create an association without LDL directly causing Alzheimer's. high LDL may occur alongside other health risks, and dementia diagnoses may combine people with different underlying brain diseases. Some studies have found no LDL–Alzheimer's relationship. In the prospective Framingham Heart Study, LDL at the examined adult life stages was not associated with later Alzheimer's disease.
Early-adult triglycerides and midlife glucose were associated with risk instead, according to the Boston University-led study. Genetic studies also fail to provide a consistent causal answer. One study of 10,578 predominantly White participants found no link between inherited predisposition to higher LDL and late-onset Alzheimer's. A Danish study of 111,194 people found no increased Alzheimer's risk from genetic variants associated with lower LDL, although its estimates were imprecise.
Dementia diagnoses can hide mixed causes
A person diagnosed with Alzheimer's dementia may have more than one type of brain damage. In an autopsy study cited by the Alzheimer's Association, 82% of 447 people thought to have Alzheimer's dementia had Alzheimer's changes plus at least one additional dementia pathology, including vascular disease.
This overlap complicates cholesterol research. A study may detect an association with dementia partly because vascular damage and Alzheimer's changes often occur together. That result would not establish that LDL directly produces the defining brain changes of Alzheimer's disease.
Do statins prevent Alzheimer's or dementia?
Randomized trials have not shown that starting statins later in life prevents cognitive decline or dementia. A Cochrane review examined two trials involving 26,340 participants with vascular risk and found no cognitive difference between treatment groups. Only 62 participants developed dementia, so the dementia estimates were imprecise.
The evidence therefore cannot support using statins specifically as a proven dementia-prevention treatment, as explained in the Cochrane review. Research using genetic proxies for LDL-lowering medicines is also inconsistent. A 2020 analysis found no support for repurposing statins, ezetimibe, or mipomersen to prevent Alzheimer's, while its PCSK9-target analysis predicted higher risk and called for continued safety monitoring. Genetic proxies can inform research, but they are not substitutes for randomized treatment trials.
What should someone with high LDL do?
Elevated LDL still deserves attention because cholesterol treatment has established cardiovascular goals. Current ACC/AHA guidance targets LDL lowering to reduce atherosclerotic cardiovascular disease, heart attack, and stroke—not as a proven Alzheimer's-prevention therapy, according to the American Heart Association's 2026 guidance. A practical conversation with a clinician should: If treatment is recommended, the sound reason is the person's cardiovascular risk—not a promise that lowering LDL will prevent Alzheimer's disease.
- Assess LDL in the context of overall cardiovascular risk.
- Clarify the cardiovascular benefit expected from treatment.
- Separate established heart and stroke goals from unproven Alzheimer's claims.
- Avoid starting, stopping, or changing cholesterol medicine solely because of dementia headlines.
